Empirical evaluation demonstrated importance of validating biomarkers for early detection of cancer in screening settings to limit the number of false-positive findings.
Empirical evaluation demonstrated importance of validating biomarkers for early detection of cancer in screening settings to limit the number of false-positive findings.
复制标题
实证评估证明了在筛查环境中验证生物标志物对于癌症早期检测的重要性，以限制假阳性结果的数量
DOI：
10.1016/j.jclinepi.2016.01.022
复制
发表时间：
2016
影响因子：
7.2
通讯作者：
Brenner H
中科院分区：
文献类型：
--
作者：
Chen H;Knebel P;Brenner H
目标寻找癌症早期检测的生物标志物是一个非常活跃的研究领域，但大多数研究都是在临床而不是筛查环境中进行的。我们旨在凭经验评估研究环境对于早期检测标记物识别和验证的作用。研究设计和设置在 35 名临床确定的结直肠癌患者和 35 名在筛查结肠镜检查中确定的结直肠癌患者中测量了一组 92 种候选癌症蛋白标记物。对于每个病例组，我们选择了 38 名在筛查结肠镜检查时未发现结直肠肿瘤的对照者。在每种情况下识别出区分病例和对照的单、二和三标志物组合，并随后在替代环境中进行验证。结果在所有情况下，最初在临床环境中检测到较高数量的预测生物标志物，但随后在筛查环境中确认的已识别生物标志物的比例要低得多。在筛查环境中识别的一、二和三标记算法的确认率分别为 50.0%、84.5% 和 74.2%，在临床环境中识别的算法的确认率为 42.9%、18.6% 和 25.7%。 结论 在真实的筛查环境中对癌症早期检测标记物的验证对于限制假阳性结果的数量非常重要。
ObjectivesSearch for biomarkers for early detection of cancer is a very active area of research, but most studies are done in clinical rather than screening settings. We aimed to empirically evaluate the role of study setting for early detection marker identification and validation.Study Design and SettingA panel of 92 candidate cancer protein markers was measured in 35 clinically identified colorectal cancer patients and 35 colorectal cancer patients identified at screening colonoscopy. For each case group, we selected 38 controls without colorectal neoplasms at screening colonoscopy. Single-, two- and three-marker combinations discriminating cases and controls were identified in each setting and subsequently validated in the alternative setting.ResultsIn all scenarios, a higher number of predictive biomarkers were initially detected in the clinical setting, but a substantially lower proportion of identified biomarkers could subsequently be confirmed in the screening setting. Confirmation rates were 50.0%, 84.5%, and 74.2% for one-, two-, and three-marker algorithms identified in the screening setting and were 42.9%, 18.6%, and 25.7% for algorithms identified in the clinical setting.ConclusionValidation of early detection markers of cancer in a true screening setting is important to limit the number of false-positive findings.
登录
查看更多内容
影响因子：
9.7
作者：
Schneider, MR;Hoeflich, A;Lahm, H
通讯作者：
Lahm, H
影响因子：
3.9
作者：
G. McCaughan;K. Sze;S. Strasser
通讯作者：
S. Strasser
影响因子：
7.2
作者：
J. AndréKnorrnerus;Pieer Leffers
通讯作者：
Pieer Leffers
DOI：
10.1158/1078-0432.ccr-07-4534
发表时间：
2008-10-01
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Taylor JM;Ankerst DP;Andridge RR
通讯作者：
Andridge RR
影响因子：
45.3
作者：
Ransohoff, David F.;Gourlay, Margaret L.
通讯作者：
Gourlay, Margaret L.